Home Cart Sign in  
Chemical Structure| 6386-38-5 Chemical Structure| 6386-38-5

Structure of 6386-38-5

Chemical Structure| 6386-38-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Nadira De Abrew, K. ; Natoli, Ted ; Lester, Cathy C. ; Wang, Xiaohong ; Shobair, Mahmoud ; Subramanian, Arvind , et al.

Abstract: Butylated hydroxytoluene (BHT) is a synthetic antioxidant widely used in many industrial sectors. BHT is a well-studied compound for which there are many favorable regulatory decisions. However, a recent opinion by the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) hypothesizes a role for BHT in endocrine disruption ANSES (2021). This opinion is based on observations in mostly rat studies where changes to thyroid physiol. are observed Enzymic induction of Cytochrome P 450-mediated thyroid hormone catabolism has been proposed as a mechanism for these observations, however, a causal relationship has not been proven. Other evidence proposed in the document includes a read across argument to butylated hydroxyanisole (BHA), another Community Rolling Action Plan (CoRAP)-listed substance with endocrine disruption concerns. We tested the hypothesis that BHT is an endocrine disruptor by using a Next Generation Risk Assessment (NGRA) method. Four different cell lines: A549, HCC1428, HepG2, and MCF7 were treated with BHT and a series of BHT analogs at 5 different concentrations, RNA was isolated from cell extracts and run on the L1000 gene array platform. A toxicogenomics-based assessment was performed by comparing BHT′s unique genomic signature to a large external database containing signatures of other compounds (including many known endocrine disruptors) to identify if any endocrine disruption-related modes of action (MoAs) are prevalent among BHT and other compounds with similar genomic signatures. In addition, we performed a toxicogenomics-based structure activity relationship (SAR) assessment of BHT and a series of structurally similar analogs to understand if endocrine disruption is a relevant MoA for chems. that are considered suitable analogs to BHT using the P&G read across framework (Wu et al., 2010). Neither BHT nor any of its analogs connected to compounds that had endocrine activity for estrogens, androgens, thyroid, or steroidogenesis.

Keywords: estrogen, androgen, or thyroid hormone receptors, or proteins integral to steroidogenesis (EATS) ; connectivity mapping ; toxicogenomics ; read across ; New Approach Methodologies (NAM) ; Next Generation Risk Assessment (NGRA)

Purchased from AmBeed: ;

Alternative Products

Product Details of [ 6386-38-5 ]

CAS No. :6386-38-5
Formula : C18H28O3
M.W : 292.41
SMILES Code : COC(=O)CCC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
MDL No. :MFCD00210461
InChI Key :PXMJCECEFTYEKE-UHFFFAOYSA-N
Pubchem ID :62603

Safety of [ 6386-38-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of [ 6386-38-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 6386-38-5 ]
  • Downstream synthetic route of [ 6386-38-5 ]

[ 6386-38-5 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 6386-38-5 ]
  • [ 128-39-2 ]
  • [ 5597-50-2 ]
  • [ 36837-50-0 ]
References: [1] Patent: CN107011149, 2017, A, . Location in patent: Paragraph 0064-0067.
  • 2
  • [ 6386-38-5 ]
  • [ 5597-50-2 ]
  • [ 36837-50-0 ]
  • [ 115-11-7 ]
References: [1] Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation), 1987, vol. 36, # 4, p. 681 - 684[2] Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1987, # 4, p. 752 - 756.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 6386-38-5 ]

Aryls

Chemical Structure| 2206682-87-1

A128364 [2206682-87-1]

11-Methyldodecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate

Similarity: 0.96

Chemical Structure| 36837-50-0

A115768 [36837-50-0]

Methyl 3-(3-(tert-butyl)-4-hydroxyphenyl)propanoate

Similarity: 0.96

Chemical Structure| 36443-68-2

A121782 [36443-68-2]

(Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(3-(3-(tert-butyl)-4-hydroxy-5-methylphenyl)propanoate)

Similarity: 0.92

Chemical Structure| 20170-32-5

A229376 [20170-32-5]

3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionic acid

Similarity: 0.91

Chemical Structure| 856169-08-9

A746290 [856169-08-9]

Methyl 2-(5-hydroxy-2,3-dihydro-1H-inden-1-yl)acetate

Similarity: 0.90

Esters

Chemical Structure| 36837-50-0

A115768 [36837-50-0]

Methyl 3-(3-(tert-butyl)-4-hydroxyphenyl)propanoate

Similarity: 0.96

Chemical Structure| 36443-68-2

A121782 [36443-68-2]

(Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(3-(3-(tert-butyl)-4-hydroxy-5-methylphenyl)propanoate)

Similarity: 0.92

Chemical Structure| 856169-08-9

A746290 [856169-08-9]

Methyl 2-(5-hydroxy-2,3-dihydro-1H-inden-1-yl)acetate

Similarity: 0.90

Chemical Structure| 22446-37-3

A143416 [22446-37-3]

Methyl 2-(2-hydroxyphenyl)acetate

Similarity: 0.88

Chemical Structure| 64360-47-0

A475543 [64360-47-0]

Methyl 2-(4-hydroxy-3-methylphenyl)acetate

Similarity: 0.88